Results 171 to 180 of about 4,565 (213)

Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination [PDF]

Expert Review of Anti-Infective Therapy, 2020
infections due to carbapenem-resistant Enterobacterales (CRE) constitute a worldwide threat and are associated with significant mortality, especially in fragile patients, and costs. Meropenem-vaborbactam (M/V) is a combination of a group 2 carbapenem with a novel cyclic boronic acid-based β-lactamase inhibitor which has shown good efficacy against KPC ...
Andrea Novelli, Gian Maria Rossolini, Mario Tumbarello   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen

International Journal of Antimicrobial Agents, 2023
Meropenem in combination with β-lactamase inhibitors (BLIs) and other drugs was tested to identify alternative treatment regimens for multidrug-resistant tuberculosis (MDR-TB).The following were performed: (1) MIC experiments; (2) static time-kill studies (STKs) with different BLIs; and (3) a hollow fibre model system of TB (HFS-TB) studies with ...
Sanjay Singh, Tawanda Gumbo, Jan-Willem Alffenaar, Gunavanthi D. Boorgula, Prem Shankar, Tania A. Thomas, Keertan Dheda, Lesibana Malinga, Prithvi Raj, Santosh Aryal, Shashikant Srivastava   +10 more
openaire   +3 more sources

Oxygenator impact on meropenem/vaborbactam in extracorporeal membrane oxygenation circuits

Perfusion, 2021
Introduction: To determine the oxygenator impact on alterations of meropenem (MEM)/vaborbactam (VBR) in a contemporary neonatal/pediatric (1/4-inch) and adolescent/adult (3/8-inch) extra corporeal membrane oxygenation (ECMO) circuit including the Quadrox-i® oxygenator.
Jeffrey J Cies, Peter Nikolos, Wayne S Moore, Nadji Giliam, Tracy Low, Daniel Marino, Jillian Deacon, Adela Enache, Arun Chopra   +8 more
openaire   +2 more sources

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme

International Journal of Antimicrobial Agents, 2018
The activity of meropenem/vaborbactam was evaluated against 11 559 Enterobacteriaceae isolates, including 330 carbapenem-resistant phenotypes (CRE) and carbapenemase genotypes collected worldwide during 2015. Antimicrobial susceptibility testing for meropenem/vaborbactam (inhibitor at 8 mg/L) and comparators was performed by the reference broth ...
Michael D Huband, Mariana Castanheira
exaly   +3 more sources

An Update on Existing and Emerging Data for Meropenem-Vaborbactam

Clinical Therapeutics, 2020
The search for new agents to treat multidrug-resistant gram-negative bacterial infections has been ongoing. Specifically, carbapenem-resistant Enterobacteriaceae (CRE) infections often exhibit multiple resistance mechanisms, including alterations in drug structure, bacterial efflux pumps, and drug permeability.
Bethany R, Shoulders, Anthony M, Casapao, Veena, Venugopalan   +2 more
openaire   +2 more sources

Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem [PDF]

Antimicrobial Agents and Chemotherapy, 2019
Vaborbactam is a novel beta-lactamase inhibitor with activity against important beta-lactamases, in particular, serine carbapenemases, and is currently approved in combination with meropenem as Vabomere for the treatment of complicated urinary tract infections, including pyelonephritis.
Mojgan Sabet, David, Olga Lomovskaya
exaly   +3 more sources